MatchMiner: An open source platform for cancer precision medicine

Author:

Klein HarryORCID,Mazor Tali,Siegel Ethan,Trukhanov Pavel,Ovalle Andrea,Vecchio Fitz Catherine Del,Zwiesler Zachary,Kumari Priti,Van Der Veen Bernd,Marriott Eric,Yu Joyce,Albayrak Adem,Barry Susan,Keller Rachel B.,MacConaill Laura E.,Lindeman Neal,Johnson Bruce E.,Rollins Barrett J.,Do Khanh T.,Beardslee Brian,Shapiro Geoffrey,Hector-Barry Suzanne,Methot John,Sholl Lynette,Lindsay James,Hassett Michael J.,Cerami Ethan

Abstract

AbstractThe systematic deployment of next generation sequencing means patient tumors can be genomically profiled and specific genetic alterations can be targeted with precision medicine (PM) drugs. More therapeutic clinical trials are needed to test new PM drugs to advance precision medicine, however, the availability of comprehensive patient sequencing data coupled with complex clinical trial eligibility has made it challenging to match patients to PM trials. To facilitate enrollment onto PM trials, we developed MatchMiner. MatchMiner is an open-source platform to computationally match genomically profiled cancer patients to PM trials. Here, we describe MatchMiner’s capabilities, outline its deployment at Dana-Farber Cancer Institute (DFCI), and characterize its impact on PM trial enrollment. MatchMiner’s two primary goals are to (1) facilitate PM trial options for all patients, and (2) accelerate trial enrollment onto PM trials. MatchMiner has 3 main modes of use: (1) patient-centric, where a clinician looks up trial options for an individual patient, (2) trial-centric, where a trial team identifies candidate patients for their trial by setting up a filter, and (3) trial search, where a clinician can find trial options for patients that have external genomic reports. From the time MatchMiner was first deployed at DFCI in March 2016 through March 2021, we curated 354 PM trials containing a broad range of genomic and clinical eligibility criteria and MatchMiner facilitated 166 trial consents (MatchMiner consents, MMC) for 159 patients. To quantify MatchMiner’s impact on trial consent, we retrospectively measured time from genomic sequencing report date to trial consent date for the 166 MMC compared to trial consents not facilitated by MatchMiner (non-MMC). We found MMC consented to trials 55 days (22%) earlier than non-MMC. MatchMiner has enabled our clinicians to match patients to PM trials and accelerated the trial enrollment decision making process.

Publisher

Cold Spring Harbor Laboratory

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3